Possibilities of drug correction of premenstrual pain manifestations
Dobrokhotova Yu.E.¹, Friptu V.G.², Grishin I. I.¹, Saprykina L.V.¹, Mazur I.A.<sup>2,3

1</sup> Russian National Research Medical University named after N.I. Pirogov, Moscow
² State University of Medicine and Pharmacy named after N. Testemitsanu, Kishinev, Moldova
³ «Medsi» Group of Companies, Moscow

The aim of this study was to determine the effectiveness of the treatment of premenstrual symptoms by prescribing a combined oral contraceptive (COC) containing drospirenone.
Patients and methods: 136 women with moderate / severe premenstrual syndrome (PMS) aged 18-45 years participated in the study. The diagnosis of PMS was based on diagnostic criteria. Patients were assigned a COC containing drospirenone (DRSP 3 mg / EE30 μg) according to the scheme for 21/7 days for 3 months. The effectiveness of the treatment was established on the basis of dynamic observation of the patients' condition when assessing the data obtained when filling out the special questionnaires.
Results: before the beginning of treatment, the patients noted a number of pain symptoms during the premenstrual period: headaches - 66.18% of cases, heaviness and pain in the breasts - 83.08%, pelvic pains - 70.58%, bloat and abdominal pains - 64,7%, muscular and joint pains - 51.47% of cases. As a result, it was shown that suppression of ovulation with the appointment of COC contributed to a decrease in the intensity of premenstrual symptoms, a decrease in the number and duration of expression of symptoms, there were statistically significant differences from the first month of treatment with a progressive positive effect. The most obvious changes were noted in the category of «heaviness and pain in the breast»: in the first month of treatment the frequency was reduced from 83.08 ± 3.21% to 56.62 ± 4.25%, after 3 months of treatment the incidence of symptoms decreased by 25.74 ± 3.75% in comparison with the initial value. The total score according to the Menstrual Distress questionnaire at the beginning of the study was 47.14 points, and after treatment it decreased to 18.71 points (p <0.001). 82.1% of patients noted improvement and 79.7% of patients considered treatment as effective.
Conclusion: the prescribed treatment contributed to the improvement of premenstrual symptoms, which was noted from the first month, and was significant by the end of the third month. Due to the effects produced by drospirenone COC, it is the drug of choice in the treatment of premenstrual symptoms.

Key words: premenstrual symptoms, cyclic mastalgia, headache, treatment of premenstrual symptoms, COC, drospirenone, suppression of ovulation.
For citation: Dobrokhotova Yu.E., Friptu V.G., Grishin I. I. et al. Possibilities of drug correction of premenstrual pain manifestations // RMJ. 2017. № 26. 
P. 1926–1929.